Selection and characterization of suitable lipid excipients for use in the manufacture of didanosine-loaded solid lipid nanoparticles and nanostructured lipid carriers

Journal of Pharmaceutical Sciences

Volumn 100, Issue 12, 2011, Pages 5185-5196

  Kasongo, Kasongo Wa ^a,b   Pardeike, Jana ^a,c   Müller, Rainer H ^a   Walker, Roderick B ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b RHODES UNIVERSITY   (South Africa)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

Calorimetry (DSC); Crystallinity; Didanosine; Nanostructured lipid carriers (NLCs); Polymorphism; Precirol ATO 5; Preformulation; Solid lipid nanoparticles (SLNs); Transcutol HP; X ray diffractometry

Indexed keywords

CAPRYOL; DIDANOSINE; DIETHYLENE GLYCOL MONOETHYL ETHER; DYNASAN; EMULCIRE; EXCIPIENT; GELEOL; GLYCEROL BEHENATE; GLYCEROL PALMITOSTEARATE; HYDROGENATED CASTOR OIL; IMWITOR; LABRAFAC; LABRAFIL LIPOFILE; LAUROGLYCOL; LIPID; MIGLYOL; NANOSTRUCTURED LIPID CARRIER; SOFTISAN; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; HEATING; MELTING POINT; MOLECULAR INTERACTION; RADIATION SCATTERING;

EID: 80054882310     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22711     Document Type: Article

References (31)

1. The United Nations Children's Fund (UNICEF) and the World Health Organization (WHO). UNICEF/WHO technical consultation: Improving access to appropriate paediatric ARV formulations. Accessed September 23, 2010, at.
2. Sweetman SC. 2002. Antivirals: Didanosine. In Martindale: The complete drug reference; Sweetman SC, Ed. 33rd ed. London: The Pharmaceutical Press, pp 618-619.
3. Nassar MN, Chen T, Reff MJ, Agharkar SN. 1993. Didanosine. In Analytical profiles of drug substances and excipients; Brittain HG, Ed. New York: Academic Press, Inc, pp 185-227.
4. Gibbon CJ. 2001. Antivirals for systemic use: Didanosine. In SAMF: South African medicines formulary; Gibbon CJ, Ed. 8th ed.Cape Town: Health and Medical Publishing Group, pp 322.
5. Perry CM, Noble S. 1999. Didanosine: An updated review of its use in HIV infection. Drugs 58:1099-1135.
6. Damle BD, Kaul S, Behr D, Knupp C. 2002. Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects. J Clin Pharmacol 42:791-797.
7. Anderson BD, Wygant MB, Xiang TX, Waugh WA, Stella VJ. 1988. Preformulation solubility and kinetic studies of 2', 3'-dideoxypurine nucleosides: Potential anti-AIDS agents. Int J Pharm 45:27-37.
8. Bekers O, Beijnen JH, Klein MJT, Burger DM, Meenhorst PL, Lombarts AJPF, Underberg WJM 1993. 2'3'-dideoxyinosine (ddI): Its chemical stability and cyclodextrin complexation in aqueous media. J Pharm Biomed Anal 11:489-493.
9. Dodge RT, Shipp KW, Miralles GD. 1998. Improved gastrointestinal tolerance and palatability of didanosine in adults by the use of paediatric powder formulation. J Assoc Nurses AIDS Care 9:27-31.
10. Bristol-Meyers Squibb Company. Electronic package insert. Videx® (didanosine): Chewable/dispersible buffered tablets, buffered powder for oral solution, paediatric powder for oral solution. Accessed January 6, 2011, at.
11. Perry CM, Balfour JA. 1996. Didanosine: An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs 52:928-962.
12. Bristol-Meyers Squibb Company. Electronic package insert. Videx® EC (didanosine) delayed release capsules, enteric-coated beadlets. Accessed January 6, 2011, at.
13. Damle BD, Mummaneni V, Kaul S, Knupp C. 2002. Lack of effect of simultaneously administered didanosine encapsulated enteric coated bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. Antimicrob Agents Chemother 46:385-391.
14. Bristol-Meyers Squibb Company. Electronic package insert: Videx® (didanosine): Paediatric powder for oral solution. Accessed January 6, 2011, at.
15. Mehnert W, Mäder K. 2001. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 47:165-196.
16. Müller RH, Radtke M, Wissing SA. 2002. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242:121-128.
17. Müller RH, Lippacher A, Gohla S. 2000. Solid lipid nanoparticles (SLN) as a carrier system for the controlled release of drugs. In Handbook of pharmaceutical controlled release technology; Wise DL, Ed. New York: Marcel Dekker, pp 377-389.
18. Jenning V, Thünemann AF, Gohla SH. 2000. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 199:167-177.
19. Müller RH, Radtke M, Wissing SA. 2002. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Delivery Rev 54:S131-S155.
20. Schöler N, Olbrich C, Tabatt K, Müller RH, Hahn H, Liesenfeld O. 2001. Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int J Pharm 221:57-67.
21. Weyhers H, Ehlers S, Hahn H, Souto EB, Müller RH. 2005. Solid lipid nanoparticles (SLN)-effect of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie 61:539-544.
22. Muller RH, Mehnert W, Lucks JS, Chwarz CS, zur Muhlen A, Wyhers H, Freitas C, Ruhl D. 1995. Solid lipid nanoparticles (SLN): An alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 41:62-69.
23. Müller RH, Mäder K, Gohla S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm 50:161-177.
24. Jaspart S, Piel G, Delattre L, Evrard B. 2005. Solid lipid microparticles: Formulation, preparation, characterization, drug release and applications. Expert Opin Drug Deliv 2:75-87.
25. Armstrong NA. 2009. Glyceryl Palmitostearate. In Handbook of pharmaceutical excipients; Rowe, RC, Sheskey PJ, Quinn ME, Eds. 6th ed. London: The Pharmaceutical Press, pp 293-294.
26. Radtke M, Souto EB, Müller RH. 2005. Nanostructured lipid carriers: A novel generation of solid lipid drug carriers. Pharm Tech Eur 17:45-50.
27. Radtke M, Müller RH. 2001. Nanostructured lipid carriers. New Drugs 2:48-52.
28. Saupe A, Wissing SA, Lenk A, Schmidt C, Müller RH. 2005. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)-structural investigations on two different carrier systems. Biomed Mater Eng 15:393-402.
29. Wa Kasongo K, Shegokar R, Müller RH, Walker RB. 2010. Formulation development and in vitro evaluation of didanosine-loaded nanostructured lipid carriers (NLC) for the potential treatment of AIDS dementia complex (ADC). Drug Dev Ind Pharm 37:396-407.
30. Müller RH, Runge SA, Ravelli V, Thünemann AF, Mehnert W, Souto EB. 2008. Cyclosporine-loaded solid lipid nanoparticles (SLN): Drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm 68:535-544.
31. Souto EB, Mehnert W, Müller RH. 2006. Polymorphic behaviour of compritol 888 ATO as bulk lipid and as SLN and NLC. J Microencapsul 23:417-433.